Yunhong Noh, President of the Korea Pharmaceutical and Bio-Pharma Manufacturers Association (KPBMA), has criticized the government's re-evaluation of foreign drug price comparison. Noh points out that making a simple drug price comparison poses problem despite differences in socioeconomic circumstances and healthcare systems between South Korea and the countries being compared to.

"South Korea faces an important turning point for leaping to the advanced country in the global new drug development field," Noh said. "The government should establish a policy by assessing comprehensive effects on the pharmaceutical and biotech industry."

Noh made this statement during the Q&A session